VistaGen Therapeutics (VSTA) Announces Engagement of MissionIR’s Investor Relations Services
VistaGen Therapeutics, Inc., a biotechnology company applying stem cell technology for drug rescue and cell therapy, has engaged MissionIR, a national investor relations consulting firm, to develop and implement a strategic investor relations campaign. Through a network of investor-oriented online websites and full suite of investor awareness services, MissionIR broadens the influence of publicly traded companies and enhances their ability to attract growth capital and improve shareholder value.
“VistaGen’s work with human stem cell technology is groundbreaking,” said Sherri Snyder, Director of Marketing at MissionIR. “The company’s versatile platform, Human Clinical Trials in a Test Tube™, provides clinically relevant predictions of potential heart toxicity of new drug candidates long before they are ever tested on humans. Guided by a management team with decades of experience, VistaGen’s stem cell technology can potentially save billions of dollars in the healthcare industry while recapturing prior R&D investment in once-promising new drug candidates.”
“We are pleased to bring MissionIR on board as our external investor relations partner,” said Shawn Singh, VistaGen’s Chief Executive Officer. “The crucial work our company is doing can fundamentally change the way medicine is developed. Paired with MissionIR’s global presence and sound investor relations programs, we can further grow our shareholder base and accelerate internal initiatives already in place to bring our stem cell technology platform to the forefront of drug development.”
Please see disclaimer on the MissionIR website: http://www.missionir.com/disclaimer